Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin) (DrugBank: Calcium, Aldosterone, Angiotensin II, Angiotensin)
7 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
17 | 多系統萎縮症 | 0 |
19 | ライソゾーム病 | 0 |
46 | 悪性関節リウマチ | 0 |
66 | IgA腎症 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
222 | 一次性ネフローゼ症候群 | 1 |
224 | 紫斑病性腎炎 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01508468 (ClinicalTrials.gov) | January 2012 | 9/12/2011 | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy | Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN) | Idiopathic Membranous Nephropathy | Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab) | Assistance Publique - Hôpitaux de Paris | NULL | Active, not recruiting | 18 Years | N/A | Both | 80 | Phase 3 | France |